PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV

On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor ipilimumab or BRAF/MEK inhibitors (for BRAF mutate...

Descripción completa

Detalles Bibliográficos
Autores principales: Davar, Diwakar, Wilson, Melissa, Pruckner, Chelsea, Kirkwood, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581502/
https://www.ncbi.nlm.nih.gov/pubmed/26448890
http://dx.doi.org/10.1155/2015/737389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581502/
https://www.ncbi.nlm.nih.gov/pubmed/26448890
http://dx.doi.org/10.1155/2015/737389

Ejemplares similares